TRML

Tourmaline Bio Inc.

TRML.US tourmalinebio.com + Research + Basket
CIK 0001827506
Employees 76
Phone 646 481 9832
Fiscal year end December
IPO May 07, 2021
Address 27 West 24th Street, New York, NY, United States, 10010
Price N/A
USD · NASDAQ
52-week range
0.00
0.00
Market Cap
1.23B
P/E Ratio
0.00
Forward P/E
0.00
Book Value
10.09
Div. Yield
N/A
% Institutions
89.13%
% Insiders
14.62%

1 Year

+81.2%

3 Year

+615.3%

10 Year

-33.5%
Description

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. Tourmaline Bio, Inc. operates as a subsidiary of Novartis AG.

Actions

Add an action for TRML.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Sandeep C. Kulkarni M.D. Co-Founder, CEO & Director 1982
Mr. Ryan Robinson CPA CFO & Treasurer 1988
Mr. W. Bradford Middlekauff J.D. Chief Business Officer, General Counsel & Corporate Secretary 1962
Dr. Susan Dana Jones Ph.D. Chief Technology Officer 1960
Ms. Kimberly Piorkowski Vice President of People, Culture & Compliance NA
Dr. Kevin B. Johnson M.B.A., Ph.D. Chief Regulatory Officer 1964
Ms. Dora Rau Senior VP & Head of Quality NA
Mr. Gerhard Hagn Pharm.D. Chief Commercial Officer NA
Dr. Emil M. deGoma M.D. Senior Vice President of Medical Research NA
Dr. Kristine Erickson O.D., Ph.D. VP & TA Head of Ophthalmology, Medical Research NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Aug 16, 2024 Sandeep Chidambar Kulkarni N/A Purchase 5.22K $13.79 $72.00K SEC
Jan 29, 2024 Mark Mcdade N/A Purchase 100.00K $32.50 $3.25M SEC
Nov 17, 2023 Parvinder Thiara N/A Purchase 1.00K $17.31 $17.31K SEC
Nov 17, 2023 Sandeep Chidambar Kulkarni N/A Purchase 4.00K $16.99 $67.96K SEC
Oct 27, 2023 Caley Castelein N/A Purchase 15.80K $14.55 $229.89K SEC
Oct 26, 2023 Sandeep Chidambar Kulkarni N/A Purchase 5.00K $12.25 $61.25K SEC
Oct 24, 2023 Aaron Kantoff N/A Purchase 7.50K $11.86 $88.95K SEC
Oct 24, 2023 Sandeep Chidambar Kulkarni N/A Purchase 4.65K $10.68 $49.66K SEC

Financial Highlights

▼
Market Cap: $1.23B
EBITDA: $-102.41M
Book Value: $10.09
Earnings/Share: $-3.44
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -20.85%
ROE (TTM): -29.62%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $993.63M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 25.69M
Shares Float: 13.13M
% Insiders: 14.62%
% Institutions: 89.13%
Shares Short: 808.96K
Shares Short (Prior Month): 982.61K
Short Ratio: 1.12
Short % Float: 3.52%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-39.00K
Gross Profit
subtotal
$-39.00K
SG&A
adjust
$-22.75M
R&D
adjust
$-66.99M
Operating Income
subtotal
$-89.73M
Other / Non-Operating Items
adjust
$16.52M
Net Income
subtotal
$-73.21M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about TRML.US!